For seven years the LCSB team worked together with international colleagues to reach this point, led by Dr Rejko Krüger.
"A very rare mutation that originated in Parkinson's could not only be identified, but the ways in which that mutation contributes to the patient's illness could be deciphered," said Dr Ibrahim Boussaad of the LCSB.
To date, there have been no clinical trials, just cultures in the lab.
It's an important step in the fight against the second most common neurodegenerative disease, only led by Alzheimer's.
It is estimated that over 7 million people worldwide have Parkinson's, a number which could double within the next 20 years due to humans growing older, and more polluted environments.
Video report in Luxembourgish:
